Join the club for FREE to access the whole archive and other member benefits.

Geron

Company focused on the telomeres and telomerase research, with interest in stem cells as well.

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Imetelstat is a novel, first-in-class telomerase inhibitor exclusively owned by Geron and being developed in hematologic myeloid malignancies. Early clinical data suggest imetelstat may have disease-modifying activity through the suppression of malignant progenitor cell clone proliferation, which allows potential recovery of normal hematopoiesis. Ongoing clinical studies of imetelstat consist of IMerge™, a Phase 2/3 clinical trial in lower risk myelodysplastic syndromes (MDS) and IMbark™, a Phase 2 trial in Intermediate-2 to High-risk myelofibrosis. Imetelstat received Fast Track designation from the United States Food and Drug Administration for the treatment of patients with transfusion-dependent anemia due to non-del(5q) lower risk MDS who are refractory or resistant to an erythroid stimulating agent.

Visit website: https://www.geron.com/

 Login to view link, or join the club to get full access to all resources and other benefits.